AstraZeneca touts Enhertu, Orpathys dual lung cancer wins amid bispecific failure
AstraZeneca reported positive results from two non-small cell lung cancer trials for Enhertu and an Orpathys-Tagrisso combination, although…
GSK to seek FDA approval for Jemperli in high-profile cancer use
In what GSK says represents a potential way to transform treatment for patients with certain types of rectal…
GSK partner Hansoh reports another phase 3 win for priority ADC
Hansoh Pharmaceutical has guided its GSK-partnered, B7-H3-directed antibody-drug conjugate (ADC) to another phase 3 win in China. Weeks after reporting…
AstraZeneca updates Ultomiris HSCT-TMA Phase III data | AZN SEC Filing
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant…
GSK setback deepens P2X3 cough drug doubts
Why it matters: P2X3 antagonists were expected to create a new treatment class for patients whose cough persists…
GSK hep B drug cures one-fifth of patients in ‘major step’
GSK is pulling back the curtain on the phase 3 success of its chronic hepatitis B drug bepirovirsen,…
AstraZeneca, after phase 3 miss, posts data behind approval bid
AstraZeneca has shared data it believes can rescue anselamimab from a phase 3 failure, linking the drug candidate to…
GSK reports 19% functional cure rate for near-approval hepatitis B drug
The placebo-controlled trials assessed the ability of bepirovirsen, an antisense oligonucleotide targeting hepatitis B transcripts, to cause functional…